Ironwood Pharmaceuticals, Inc.

Total Valuation

Ironwood Pharmaceuticals, Inc. carries a market capitalization of 533.35M, placing it among publicly traded companies globally. Its enterprise value stands at 947.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Ironwood Pharmaceuticals, Inc. currently has 164.61M shares outstanding.

Valuation Ratios

Ironwood Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 5.58. The price-to-sales ratio is 1.58, and the price-to-book ratio stands at -0.35.

Enterprise Valuation

On an enterprise value basis, Ironwood Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 4.65 and an EV/FCF ratio of 7.16. The EV/Sales ratio of 2.62 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 4.69 provides insight into valuation relative to core operating earnings.

Financial Position

Ironwood Pharmaceuticals, Inc. maintains a current ratio of 1.41, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -275.10, indicating conservative leverage, while an interest coverage ratio of 6.05 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Ironwood Pharmaceuticals, Inc. has paid 69.29M in income taxes, reflecting an effective tax rate of 40.41.

Stock Price Statistics

Ironwood Pharmaceuticals, Inc.'s stock has gained approximately 431.23463% over the past 52 weeks. The 50-day moving average sits at 3.84, while the 200-day moving average is 3.13.

Income Statement

Over the trailing twelve months, Ironwood Pharmaceuticals, Inc. generated 361.51M in revenue and converted that into 102.18M in net income, yielding earnings per share of 0.60. EBITDA reached 203.69M, while operating income came in at 201.84M.

Balance Sheet

Ironwood Pharmaceuticals, Inc. holds 220.47M in cash and equivalents against 597.36M in total debt, resulting in a net debt position of 364.38M. Total book value stands at -1.63B, with working capital of 95.99M providing operational flexibility.

Cash Flow

Ironwood Pharmaceuticals, Inc. produced 112.21M in operating cash flow over the past twelve months. After subtracting -3,000.00 in capital expenditures, free cash flow totaled 112.21M - equivalent to 0.69 per share.

Margins

Ironwood Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 55.83 and net profit margin of 28.26 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Ironwood Pharmaceuticals, Inc.'s most recent stock split took place on April 2, 2019 with a 500:597 split ratio.

Scores

Ironwood Pharmaceuticals, Inc. posts an Altman Z-Score of -2.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.